Impact of Liver Metastases and Number of Metastatic Sites on Immune-Checkpoint Inhibitors Efficacy in Patients with Different Solid Tumors: A Retrospective Study.

Autor:	Maugeais M; Oncology Department, Centre Hospitalier Lyon Sud, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), 69495 Pierre-Bénite, France., Péron J; Oncology Department, Centre Hospitalier Lyon Sud, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), 69495 Pierre-Bénite, France.; Université Claude Bernard Lyon 1, 69100 Villeurbanne, France.; ImmuCare (Immunology Cancer Research), Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), 69229 Lyon, France.; CNRS, UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Equipe Biostatistique-Santé, 69100 Villeurbanne, France., Dalle S; Université Claude Bernard Lyon 1, 69100 Villeurbanne, France.; ImmuCare (Immunology Cancer Research), Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), 69229 Lyon, France.; Dermatology Department, Centre Hospitalier Lyon Sud, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), 69495 Pierre-Bénite, France., Boespflug A; Université Claude Bernard Lyon 1, 69100 Villeurbanne, France.; ImmuCare (Immunology Cancer Research), Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), 69229 Lyon, France.; Dermatology Department, Centre Hospitalier Lyon Sud, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), 69495 Pierre-Bénite, France., Duruissaux M; Université Claude Bernard Lyon 1, 69100 Villeurbanne, France.; ImmuCare (Immunology Cancer Research), Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), 69229 Lyon, France.; Department of Respiratory Medicine, Groupement Hospitalier Est, Hôpital Louis-Pradel, URCOT, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), 69500 Bron, France.; Centre de Recherche en Cancérologie, 69008 Lyon, France., Corbaux P; Oncology Department, Centre Hospitalier Lyon Sud, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), 69495 Pierre-Bénite, France., Reverdy T; Oncology Department, Centre Hospitalier Lyon Sud, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), 69495 Pierre-Bénite, France., Sahin G; Oncology Department, Centre Hospitalier Lyon Sud, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), 69495 Pierre-Bénite, France., Rabier A; Oncology Department, Centre Hospitalier Lyon Sud, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), 69495 Pierre-Bénite, France., Lopez J; Université Claude Bernard Lyon 1, 69100 Villeurbanne, France.; ImmuCare (Immunology Cancer Research), Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), 69229 Lyon, France.; Department of Biochemistry and Molecular Biology, Centre Hospitalier Lyon Sud, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), 69495 Pierre-Bénite, France.; Cancer Research Center of Lyon, INSERMU1052, 69007 Lyon, France., Freymond N; ImmuCare (Immunology Cancer Research), Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), 69229 Lyon, France.; Department of Thoracic Oncology, Hôpital Lyon Sud, URCOT, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), 69310 Pierre-Bénite, France., Maillet D; Oncology Department, Centre Hospitalier Lyon Sud, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), 69495 Pierre-Bénite, France.; ImmuCare (Immunology Cancer Research), Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), 69229 Lyon, France.; Université de Médecine Jacques Lisfranc, 42270 Saint-Etienne, France.
Jazyk:	angličtina
Zdroj:	Biomedicines [Biomedicines] 2022 Dec 29; Vol. 11 (1). Date of Electronic Publication: 2022 Dec 29.
DOI:	10.3390/biomedicines11010083
Abstrakt:	Background: ICIs have dramatically improved patient outcomes in different malignancies. However, the impact of liver metastases (LM) and number of metastatic sites (MS) remains unclear in patients treated with single-agent anti-PD(L)1. Methods: We aimed to assess the prognostic impact of LM and MS number on progression-free survival (PFS) and overall survival (OS) in a large single-arm retrospective multicentric cohort (IMMUCARE) of patients treated with anti-PD(L)-1 for different solid tumors. Results: A total of 759 patients were enrolled from January 2012 to October 2018. The primary tumor types were non-small cell lung cancer (71%), melanoma (19%), or urologic cancer (10%). At the time of ICI initiation, 167 patients (22%) had LM and 370 patients (49%) had more than MS. LM was associated with a shorter median PFS of 1.9 months (95% CI: 1.8−2.5) vs. 4.0 months (95% CI: 3.6−5.4) in patients without LM (p < 0.001). The median OS of patients with LM was of 5.2 months (95% CI: 4.0−7.7) compared with 12.8 months (95% CI: 11.2−15.1) (p < 0.001). Interestingly, LM were not associated with shorter PFS, or OS compared to other MS types (brain, bone, or lung) in patients with only one MS. Patients with multiple MS also had poor clinical outcomes compared to patients with only one MS. The presence of LM and MS number were independent prognostic factors on overall survival. Conclusion: The presence of LM or multiple MS were associated with poorer survival outcomes in patients treated with anti-PD(L)-1.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu